Compugen (XTAE:CGEN) Change In Inventory : ₪0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Compugen Change In Inventory?

Compugen's change in inventory for the quarter that ended in Dec. 2024 was ₪0.00 Mil. It means Compugen's inventory stayed the same from Sep. 2024 to Dec. 2024 .

Compugen's change in inventory for the fiscal year that ended in Dec. 2024 was ₪0.00 Mil. It means Compugen's inventory stayed the same from Dec. 2023 to Dec. 2024 .

Compugen's Total Inventories for the quarter that ended in Dec. 2024 was ₪0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Compugen's Days Inventory for the quarter that ended in Dec. 2024 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Compugen's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.

Compugen Change In Inventory Historical Data

The historical data trend for Compugen's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Change In Inventory Chart

Compugen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

Compugen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Compugen Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.00 Mil.

Compugen (XTAE:CGEN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Compugen's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	2.401	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Compugen's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	2.401	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Compugen's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	5.233
	=	0.00

Compugen Change In Inventory Related Terms

Thank you for viewing the detailed overview of Compugen's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (XTAE:CGEN) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

CGEN:USA

Address

26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849

Website

https://www.cgen.com

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.